Drug Profile
KRL 401
Alternative Names: KRL-401Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Krele Pharmaceuticals
- Developer Krele Pharmaceuticals Inc
- Class Behavioural disorder therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Attention-deficit-hyperactivity-disorder in USA
- 26 Mar 2009 Clinical trials in Attention-deficit hyperactivity disorder in USA (unspecified route)